epratuzumab-thorium-227 (BAY1862864) / Bayer - LARVOL DELTA

Thorium-227-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study. (PubMed, Cancer Biother Radiopharm) - P1 | "BAY 1862864 was safe and tolerated in patients with R/R-NHL. The Clinical Trial Registration numbers: NCT02581878 and EudraCT 2014-004140-36."

Journal • P1 data • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • CD22

Bayer to Present New Clinical Data in Indolent non-Hodgkin's Lymphoma and Additional Research on its Oncology Portfolio at AACR Annual Meeting 2021 (Businesswire) - "Oral presentation in Clinical Trials Plenary Session on April 10 to highlight the Phase III trial CHRONOS-3 evaluating the investigational combination of Aliqopa® (copanlisib) plus rituximab compared to rituximab and placebo in relapsed indolent non-Hodgkin's Lymphoma (iNHL); New data also include research into Bayer’s biomarker-driven treatment Vitrakvi® (larotrectinib) on long-term outcomes in patients with TRK fusion cancer and biomarker research in this patient population; Data from NUBEQA® (darolutamide), Xofigo® (radium Ra 223 dichloride), and targeted thorium conjugates (TTC) from Bayer’s Targeted Alpha Therapy platform will be showcased."

Clinical data • P3 data • Patient reported outcomes • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology

Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1; N=21; Completed; Sponsor: Bayer; Active, not recruiting ➔ Completed

Clinical • Trial completion

Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1; N=21; Active, not recruiting; Sponsor: Bayer; Recruiting ➔ Active, not recruiting; N=60 ➔ 21; Trial completion date: Oct 2020 ➔ Dec 2019; Trial primary completion date: Mar 2020 ➔ Apr 2019

Clinical • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date

Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Bayer; Trial completion date: Apr 2020 ➔ Oct 2020

Clinical • Trial completion date